<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9275">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05701501</url>
  </required_header>
  <id_info>
    <org_study_id>VitB5</org_study_id>
    <nct_id>NCT05701501</nct_id>
  </id_info>
  <brief_title>Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD</brief_title>
  <official_title>Clinical Study of Vitamin B5 in Adjuvant Treatment of Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with IBD are randomized to oral administration of vitamin B5 and placebo based on&#xD;
      the standard treatment, exploring whether Vitamin B5 can increase the clinical remission rate&#xD;
      of IBD patients and improve the treatment effect.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2023</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission rate</measure>
    <time_frame>Through study completion, an average of 12 months.</time_frame>
    <description>To evaluate the improvement effect of clinical remission rate (Mayo score â‰¤ 2 points and no single sub-score&gt;1 point; CDAI score&lt;150) in IBD patients after 12 weeks of oral Vitamin B5 while taking routine treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity score of IBD patients</measure>
    <time_frame>Through study completion, an average of 12 months.</time_frame>
    <description>Modified Mayo score or CDAI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological remission</measure>
    <time_frame>Through study completion, an average of 12 months.</time_frame>
    <description>Based on the Geboes scale. No or slight increase of chronic inflammatory infiltration in lamina propria, no neutrophils in lamina propria or epithelium, no persistent clinical response of erosion, ulcer or granulation tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Through study completion, an average of 12 months.</time_frame>
    <description>Modified Mayo score decreased by 2 points and 30% from baseline+rectal bleeding score decreased by 1 point or absolute rectal bleeding score decreased by 1 point.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Vitamin B5 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on the standard IBD treatment, Vitamin B5 (5mg/tablet) is given orally three times a day, four tablets each time, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Based on the standard IBD treatment, the same type of placebo tablets are given orally three times a day, four tablets each time, for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B5 Tablets</intervention_name>
    <description>The experimental group was given Vitamin tablets (5mg/tablet) based on the standard IBD treatment.</description>
    <arm_group_label>Vitamin B5 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The control group was given placebo tablets of the same type based on the standard IBD treatment.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with IBD according to the consensus on the diagnosis and treatment&#xD;
             of inflammatory bowel disease (Beijing, 2018, DOI:10.19538/j.nk2018090106);&#xD;
&#xD;
          -  Have complete medical history data;&#xD;
&#xD;
          -  Volunteer to participate in this clinical trial and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemophilic patients;&#xD;
&#xD;
          -  There are abdominal abscesses, toxic megacolon, fulminant colitis, partial colectomy,&#xD;
             or total colectomy;&#xD;
&#xD;
          -  Other autoimmune diseases, hematological diseases, tumors, acute infection, severe&#xD;
             liver and kidney insufficiency, serious diseases such as severe anemia, neutropenia,&#xD;
             heart failure, organic heart disease, hepatitis B, liver cirrhosis, kidney disease and&#xD;
             mental diseases;&#xD;
&#xD;
          -  Take calcium pantothenate preparation in recent 3 months;&#xD;
&#xD;
          -  Have a history of abuse of psychoactive substances;&#xD;
&#xD;
          -  Pregnant or lactating women, or plan to be pregnant in the next 6 months;&#xD;
&#xD;
          -  Nervous system diseases: such as Alzheimer's disease, stroke, Parkinson's disease;&#xD;
&#xD;
          -  Participate in other clinical trials in the past 6 months;&#xD;
&#xD;
          -  Incomplete medical record information (including gender, age, diagnosis information,&#xD;
             colonoscopy results, pathological diagnosis results and other demographic data)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoshen Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhaoshen Li, PhD, MD</last_name>
    <phone>+86-21-25070552</phone>
    <email>zhaoshenlismmu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>zhaoshen Li, MD</last_name>
      <phone>86-21-81873241</phone>
      <email>zhaoshenlismmu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 18, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>January 18, 2023</last_update_submitted>
  <last_update_submitted_qc>January 18, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoshen Li</investigator_full_name>
    <investigator_title>Director of gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>Vitamin B5,treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantothenic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

